J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance

Johnson & Johnson’s (JNJ) fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items, including which, reported earnings were $1.41 per share, down 17.1% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Sales of this drug and medical devices giant came in at $22.52 billion, which marginally beat the ...